Lutetium (177Lu) chloride
Lutetium (177Lu) chloride
Lutetium (177Lu) chloride is a radioactive compound used in nuclear medicine for radiotherapy and diagnostic imaging. It is composed of the isotope Lutetium-177 and chloride ions. This compound is particularly significant in the treatment of certain types of cancer, including neuroendocrine tumors and prostate cancer.
Properties[edit]
Lutetium-177 is a beta emitter with a half-life of approximately 6.65 days. It decays to stable Hafnium-177 through the emission of beta particles and gamma radiation. The beta particles are effective in destroying cancer cells, while the gamma radiation can be used for imaging purposes.
Applications[edit]
Lutetium (177Lu) chloride is primarily used in targeted radionuclide therapy. It is often conjugated with peptides or antibodies that specifically target cancer cells, allowing for precise delivery of radiation to the tumor site while minimizing damage to surrounding healthy tissue.
Neuroendocrine Tumors[edit]
One of the most common applications of Lutetium (177Lu) chloride is in the treatment of neuroendocrine tumors. These tumors can be targeted using peptide receptor radionuclide therapy (PRRT), where the compound is linked to a peptide that binds to receptors on the tumor cells.
Prostate Cancer[edit]
Lutetium (177Lu) chloride is also used in the treatment of prostate cancer, particularly in cases where the cancer has spread to other parts of the body. It is often linked to molecules that target prostate-specific membrane antigen (PSMA), a protein commonly found on prostate cancer cells.
Production[edit]
Lutetium-177 is typically produced in a nuclear reactor through the irradiation of Ytterbium-176 or Lutetium-176. The resulting Lutetium-177 is then chemically separated and combined with chloride ions to form Lutetium (177Lu) chloride.
Safety and Handling[edit]
As a radioactive substance, Lutetium (177Lu) chloride must be handled with care. Proper radiation protection measures, including the use of lead shielding and personal protective equipment, are essential to minimize exposure to radiation.
Related Pages[edit]
- Nuclear medicine
- Radiotherapy
- Neuroendocrine tumors
- Prostate cancer
- Peptide receptor radionuclide therapy
- Prostate-specific membrane antigen
- Beta emitter
- Gamma radiation
Categories[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
